

GenOnc BRCA1 BRCA 2 Panel

GenOnc BRCA1 BRCA 2 Panel

Introduction

GenOnc Germline and somatic mutations of BRCA genes have been shown, in clinical trials of advanced ovarian cancer, to induce favorable responses to a class of drugs known as PARP inhibitors. BRCA genes are now important biomarkers for the management of ovarian cancer. The BRCA1 and BRCA2 GeneRead DNaseq Targeted Panel has been designed to enable comprehensive and efficient analysis of the two genes from blood and FFPE samples. The panel is part of a sample-to-insight workflow that enables you to go from DNA sample to interpreted variants in 3 days.

Experimentally verified 100% coverage.

Regions targeted	Coding regions and 20 bp intron-exon junctions
No. of bases targeted	21472
Average amplicon length	150 bp
Primer pools	4
Total input DNA	40 ng
Number of amplicons	250
Specificity	97.8%
Uniformity (0.2x mean)	99%
% bases callable according to GATK Callable-Loci Walker	100%